$31.82
3.31% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$31.82
+0.11 0.35% 1M
+11.38 55.68% 6M
+1.02 3.31% YTD
+10.82 51.52% 1Y
-10.56 24.92% 3Y
-8.94 21.93% 5Y
+18.37 136.65% 10Y
+28.05 743.58% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+1.02 3.31%
ISIN
US3723032062
Symbol
GMAB
Industry

New AI Insights on Genmab - ADR Insights AI Insights on Genmab - ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$19.6b
Enterprise Value
$19.1b
Net debt
positive
Cash
$535.2m
Shares outstanding
61.6m
Valuation (TTM | estimate)
P/E
8.5 | 11.3
P/S
34.8 | 33.5
EV/Sales
33.9 | 32.6
EV/FCF
101.0
P/B
21.7
Financial Health
Equity Ratio
80.1%
Return on Equity
22.3%
ROCE
21.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$562.1m | $585.4m
EBITDA
$217.6m | $225.5m
EBIT
$207.1m | $210.9m
Net Income
$232.5m | $174.0m
Free Cash Flow
$188.8m
Growth (TTM | estimate)
Revenue
24.7% | 19.5%
EBITDA
42.3% | 34.1%
EBIT
41.8% | 30.9%
Net Income
119.8% | -2.5%
Free Cash Flow
26.2%
Margin (TTM | estimate)
Gross
94.3%
EBITDA
38.7% | 38.5%
EBIT
36.9%
Net
41.4% | 29.7%
Free Cash Flow
33.6%
More
EPS
$3.7
FCF per Share
$3.1
Short interest
1.9%
Employees
3k
Rev per Employee
$180.0k
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Genmab - ADR forecast:

17x Buy
63%
8x Hold
30%
2x Sell
7%

Analyst Opinions

27 Analysts have issued a Genmab - ADR forecast:

Buy
63%
Hold
30%
Sell
7%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
562 562
25% 25%
100%
- Direct Costs 32 32
82% 82%
6%
530 530
22% 22%
94%
- Selling and Administrative Expenses 94 94
16% 16%
17%
- Research and Development Expense 229 229
11% 11%
41%
218 218
42% 42%
39%
- Depreciation and Amortization 10 10
53% 53%
2%
EBIT (Operating Income) EBIT 207 207
42% 42%
37%
Net Profit 232 232
120% 120%
41%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Negative
Reuters
5 days ago
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday.
Neutral
Business Wire
5 days ago
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab's strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date ...
Neutral
GlobeNewsWire
5 days ago
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher ‑ impact opportunities across Genmab's late ‑ stage pipeline and increasingly competitive landscape This decision does not impact Genmab's full ‑ year 2025 financial guidance COPENHAGEN, Denmark; December 29, 2025 – Genmab A/S (Nasdaq: GMAB) anno...
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today